What happens when your company relies on the startups your venture fund backs? A fund can hit its return target even as the parent company loses a supplier it depends on. In this episode of Corporate Venturing Insider, Nicolas Sauvage speaks with Dave Stevenson, COO, managing director, and founding partner of Merck’s Global Health Innovation Fund. Dave explains how the fund’s investment strategy reflects the fact that more than two-thirds of its portfolio companies go on to partner with Merck. From recruiting patients for clinical trials to shipping temperature-sensitive medicines, Dave shares how Merck helps startups scale and reach customers. He also explains why an introduction to someone with a real business need and a budget is one of the most valuable things a corporate investor can offer a founder. Recorded July 13, 2026.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Welcome to today's Corporate Venturing Insider. so glad to have Dave with me. Dave, I think it was, like, two years ago we talked about you on the show. I'm so glad you'll join us. You have a huge amount of experience, I think 16 years of experience in corporate venturing. Thank you. Really thrilled to be here. It's long overdue So I always start with that simple question How did you get into corporate venturing? What was your journey into corporate venturing?
Completely by accident. I, did not intend to wind up with a career in venture. I couldn't be more happy with where I am. I think it's one of the most amazing roles you can have in any corporation and in the ecosystem in general. but really by accident. My-- I came into, what's my parent company, which is known as Merck in North America, MSD outside of North America. I came in a strategy role, which was my background. I, did strategy consulting for a very long time.
so I was always on sort of the advisory side of the world. but when I came in, MSD was at a crossroads, really trying to figure out how to deal with a healthcare environment that was changing rapidly in which, healthcare data was significantly more important, and all that data was being generated outside of our walls. And so did a lot of work with our executive committee, really helping to restructure internally how we responded to that.
but then the larger strategy question bubbles up, which is, hey, if this is an industry that's really gonna shape how healthcare not only gets delivered but paid for, how do you wanna play in it? Do you want to, maybe think about acquiring businesses and going into those businesses? but if they're gonna be fundamentally critical to how you operate your business, you certainly want to at least shape them. And so the, the strategic response was to start the venture fund, and that was really the intent and remains the intent
today of if there are innovations that can help pharmaceutical companies broadly more effectively deliver life-saving medicines to patients, we really wanna scale those as fast as possible. And so that's what we do. Our, fund's mission really is we invest in things that help pharmaceutical companies discover, develop, distribute, provide access to life-saving medications, life-improving medications, and that's really the mission.
So again, an accident, but, when, when we started the fund, we hired in Bill Taranto, who's still my boss. Bill and I talked the first day, and he made me the offer to come in. I've never looked back Now, part of it, I think, related to your role is operating discipline, and I want to frame it now in terms of investment advantage. you explain where operating discipline create an investment advantage?
I think it's on both sides of the equation of, the, the value you're delivering, right? So if you have-- I'm just starting with the financial value, because again, it has to be financial and strategic. Yep If you have discipline on the financial s-side, it's not that different than a traditional VC, right? It's really just trying to back into how you're hitting your IRR thresholds.
it's making sure that you're asking all the right questions and not, doing investments that perhaps are subsidizing a business that shouldn't exist in the world because it, quote-unquote, "has strategic value." those are the ones that tend to lead to you having awkward conversations a couple years later on, why your financial results aren't as good as they should be. so I think, the financial discipline's really key. one piece I would make really abundantly clear is I think you have to be really, clear on how your portfolio construction
ties to both the IRR result that you're aiming for, as well as to the portfolio side of creating strategic value. And so to, to get a little more crystal clear about what I'm talking about here. Look, end of the day, here at GHI, over two-thirds of our companies ultimately wind up partnering with MSD, right? So MSD is reliant on our portfolio companies to deliver value to customers, to shareholders
Well, if I have a traditional VC portfolio construction model, two-thirds of my companies are gonna go out of business And I'm gonna generate all of my returns off of the two to three really big winners. That doesn't work for us. Because end of the day, if I generate a great IRR because we had three huge winners, but 40 losers, that's a problem because now I'm having awkward conversations of "Hey, I know you
partnered with our portfolio company, but sorry, they went out of business And so that doesn't work for us. And so from a portfolio construction standpoint, I'm really looking at later stage capital. I'm looking at if I can get a 2x to 3x on the vast majority of my portfolio, and yeah, if I get a 10X or a 20X or a bit more, that's great. We'll take it. take it Yeah. So on the strategic side, obviously it's, as a platform, right?
How do you create value is your question, right? And so you're trying to organize yourself so that you have links and tight integration back into the organization, so that when I do find a company that solves a problem, there's a, there is that natural partnering that's gonna happen. And so the way we do that is we actually get-- we're embedded with the business. We go in and talk with our business partners, and because many of us are operators, we understand their issues already.
but we're able to say, "Hey, So in our world, like finding patients for clinical trials is obviously a really big issue for pharma companies. So when we go in and talk to the organization about how they're thinking about leveraging technology, how they're thinking about finding untapped patient populations, we can quickly turn that around and say, we've seen two or three companies that are a little early stage, but with our investment, we can get them to the point where they would be scaled and robust enough to partner with you."
And so when we get those types of signals, it's an easy investment for us to make because we know there's a built-in buyer on the back end, and that makes the flywheel go, right? So when, MSD comes on as a partner, drives revenue, by the way, it also helps to validate it for the rest of the industry. So we tend to see other pharma companies coming in and you see that lift, right? Which creates the value back on the financial side.
And when it works well, it works great. obviously we don't get them all right. occasionally they, they-- the technology doesn't pan out or someone better comes along or whatever else happens. But because we've constructed the portfolio the way we have, you know, it's not a high-risk portfolio, right? I don't have a ton of technology risk. I don't have a ton of, what I would call business risk, in that if we can
deliver it, there is a buyer who will in fact drive the revenue for us. And that's, I think, the, value of our platforms. right? And so oftentimes we'll be talking to folks in their, series A or earlier, even advising them on, "Hey, we don't invest that early, but these are the types of things we like to see," or, "You should talk to these investors because we tend to work with them downstream."
I think it's really critical to understand how you build an ecosystem, and it can lead to some creative approaches as well. I'll share one which is in our supply chain area. we've actually invested using, private equity money, right? So private equity players who are scaling a much larger platform around cold chain shipping, which is a really important space for pharma and critically for
MSD. By writing a larger check alongside private equity players, we've been able to scale this entity, particularly during the early pandemic, where it really made a difference to MSD to have this scaled so quickly. But what we've been able to do is actually invest in earlier stage tech where MSD's not partnered with that early stage company But AeroSafe which is our portfolio company, is.
And so we're look-- we're talking with our supply chain folks saying, "Hey, what do you need? We need cold chain, but we need it with these functions, this functionality." We can invest in earlier stage companies that then partner with our portfolio company to drive that ecosystem faster. And so it makes MSD's life easier because they only have to contract with one player, but they're getting broader capability faster because of the way we can think about building an ecosystem. And again, it's just one of the, the creative ways as a CVC, you can
really help shape markets if you play throughout the, continuum of capital I think there is one thing I really liked you mentioned is 2/3 of your portfolio end up engaging with your mothership For the entrepreneurs in the audience, I think that's really meaningful. that declares intent. On the flip side, maybe for them, which corporate interactions do you think deserve founders' time and which ones doesn't?
Okay. look, so we're, pretty straightforward with both, our entrepreneurs that we talk with, whether they're portfolio company or perspectives, as well as with, our MSD colleagues. We're-- We really play the role of broker or matchmaker, right? we, understand the need and what the problem is, and we, we understand what solutions we should be looking for,
and we scout and find those solutions and try and help from a consulting perspective, bring those parties together. I think the challenge is, if you talk to other VCs, if you talk to entrepreneurs, they're like, "Get me a meeting." look, I can find no shortage of, personnel here in our businesses that would love to waste your time.
And it's, no offense to them, right? they're, curious, they wanna learn, but they don't have a budget, right? There's, no executive buy-in that it's… So we're really trying to qualify leads, and that's where I think, as a CVC, the biggest, advantage you can provide is a qualified lead And, I think one of the things that, we talk about both internally to our team, but then also the same concept applied
to founders and entrepreneurs is your s- your scarcest resource is not capital. It's hours. And so return on hours is a really, important concept that we drive both within our team, right? like within the organization, there's no shortage of people who wanna spend time with us. How do you find the people that actually have there's a mandate, it's in the budget, and somebody's getting canned if this doesn't happen.
Yep that's a motivated buyer, right? for the people who are curious or I was going to say it's context which you would know, which probably no one outside would be able to tell look, really good salespeople can figure that out pretty quickly. But agreed. I think it's something that any CVC that's integrated into the business should know that, right?
And don't make them-- like stuff changes, right? People move, people get fired, like there's reorgs. Like all kinds of stuff happens where that changes. But truly understanding where the priorities are in the org, how important they are, and is this like one of those like, "Hey, we're just looking for a press release here," versus, "Hey, we're actually looking to drive a business result here." Sorting through those is the important part and just trying to figure out, okay, like who's actually trying to drive the business and let's spend our time there.
Yeah. Clearly, there's one thing about measurement. We talked about what you need to measure, the narratives you can build on top of these measurements. But now with your perspective of 16 years, what do you think mature CVCs can stop measuring over time? I don't have a great answer to that one. I think it, it's, there's a couple of-- metrics that I actually really hate, IRR being one of them. I just, my interim IRR is like a stupid metric.
It just, it tells me nothing. Doesn't tell me what my returns are going to be. It doesn't tell me what my returns were. It's just it's a point in time, whatever. I think when it comes down to the strategic side, this is where I don't think there's any one metric or set of metrics that absolutely nails it. Because again, to me, it comes down to the narrative, and the narrative is also variable on, who are you and why are you investing and what's important?
And so the way I, would put it is, we have the, motherhood, apple pie kind of high level, we are, helping to find patients to run clinical trials. We are helping to discover better molecules. We are helping to ensure that patients, get their medications. we're providing market access. end of the day, we are helping patients get better medicines, period.
And everything we do ties back to one of those levers that provides better medications to patients. it's how you then track back to then specifically if we're talking about clinical trials and access to trial populations, okay, then where did you invest and like what areas are problems and how did you address that problem? And can you provide metrics of whatever it is, increase in
number of patients, dollars saved, productivity gain, whatever it is. How do you start saying that, look, in aggregate we had a very positive impact on finding, trial populations and then specifically we did this, And so it's that sort of accumulation of narratives or let's call them case studies under the narrative. That's what really helps us drive the reason to believe.
And again, it can be widely varied. on the supply chain side, yeah, it could be like cost savings or, doses saved, that kind of stuff. It could also be like wastewater reduction Yep So there's a lot of ways we can show that really it backs into what's the shareholder value you're delivering? 'Cause let's not lose sight of, when your CFO is looking at you and evaluating your program, it really comes down to A, the high level question of does this unit provide shareholder value, contribute to it, right?
And then B, this is the good CFOs, which ours happens to be one. They ask the second level question of and by the way, does where they're allocating their capital tie to where the organization is allocating their capital to make sure that it's all aligned It match. At least it And because we're integrated with the business, that, matches. Yeah. No, I think it's a good golden nugget to end this podcast interview.
You have to make sure that show how it match value creation. So thank you, Dave. It was really good. You had so many candid answers, which I really appreciate it Thank you
What should founders look for in an investor who will also take a seat on their board? In this episode of Corporate Venturing Insider, Nicolas Sauvage speaks with Ray Lane, former president and COO of Oracle, about what...
Can landing a big corporate customer put your startup at risk? Benji Coetzee, Chief Strategy and Growth Officer at KPN, joins Nicolas Sauvage to explore the gap between corporate timelines and startup survival. Drawing...
What makes an investor’s network useful to a founder? Nicolas Sauvage speaks with Lu Zhang, founder of Fusion Fund, about building relationships around a startup’s actual needs. Lu explains how Fusion Fund’s CXO,...
Recorded on July 24, 2026, this episode of Corporate Venturing Insider features Nicolas Sauvage in conversation with Sriram Viswanathan, Founding Managing Partner at Celesta Capital and an early member of Intel Capital....
Filmed at the GCVI 2026 Summit in Monterey, Corporate Venturing Insider #126 features Nicolas Sauvage in conversation with Barbry McGann, co-head of Workday Ventures. Barbry shares how a career in enterprise software...